XML 33 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 11 - Stock-based Compensation Stock
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

11. Stock-Based Compensation Stock

 

2015 Equity Plan

 

The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to 4.0% of the total shares of the Company’s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company’s Board. As of June 30, 2024, there were 23,631 shares available for future issuance under the 2015 Equity Plan.

 

2018 Employee, Director and Consultant Equity Incentive Plan

 

On March 28, 2018, EIP adopted the 2018 Plan, which was assumed by the Company pursuant to and in accordance with the terms of the Merger Agreement. Under the 2018 Plan, the Company may issue incentive stock options, non-qualified stock options, stock grants, and other stock-based awards to employees, directors, and consultants, as specified in the 2018 Plan and subject to applicable SEC and Nasdaq rules and regulations. The Board has the authority to determine to whom options or stock will be granted, the number of shares, the term, and the exercise price. Options granted under the 2018 Plan have a term of up to ten years and generally vest over a four-year period with 25% of the options vesting after one-year of service and the remainder vesting monthly thereafter. As of June 30, 2024, there were no shares available for issuance.

 

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:

 

   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Research and development

  $ 40,337     $ 31,022     $ 104,134     $ 71,148  

General and administrative

    538,244       31,230       692,662       62,344  

Total stock-based compensation expense

  $ 578,581     $ 62,252     $ 796,796     $ 133,492  

 

The following table summarizes the activity related to all stock option grants for the six months ended June 30, 2024:

 

   

Number of

Options

   

Weighted

average

exercise price

per share

   

Weighted

average

remaining

contractual life

(in years)

   

Aggregate

intrinsic value

 

Balance at January 1, 2024

    349,374     $ 51.15                  

Granted

    207,284       11.23                  

Cancelled/Expired

    (23,354 )     114.18                  

Outstanding at June 30, 2024

    533,304     $ 32.87       8.4        

Exercisable at June 30, 2024

    228,508     $ 64.13       6.7        

 

 

The Black-Scholes option pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions: 

 

   

Six Months Ended

June 30,

 
   

2024

 

Expected term (in years)

  5.25 - 5.76  

Risk-free interest rate

  4.06 - 4.46%  

Expected volatility

  76.87 - 80.03%  

Dividend yield

       

 

There were no stock option grants during the six months ended June 30, 2023.

 

At June 30, 2024, there was $1.7 million of unrecognized compensation expense that will be recognized over a weighted-average period of 1.9 years.

 

During the six months ended June 30, 2024 the Company granted 39,721 options in lieu of 2023 executive bonus compensation.

 

Effective May 31, 2024, the employment of the Company's former Chief Financial Officer was terminated. Based on the terms of his severance agreement, unvested shares under previously granted option awards will to continue to vest on the schedule provided for in the applicable option award agreement through September 31, 2025. The Company accounted for the change in vesting terms as an improbable-to-probable modification of his stock options and recognized $0.3 million of expense in relation to this modification. In addition, the exercise period for any shares under previously granted option awards vested as of May 31, 2024 was extended to September 30, 2025. The Company accounted for the change in exercise terms as a probable-to-probable modification of his stock options and recognized $12,000 of expense in relation to this modification.